In Russia, including the Omsk region, withdrew the license to sell the drug “Bioparoks”.
As reported on the website Roszdravnadzor, citing a notice from the manufacturer “Bioparox” (laboratory “Servier”), cause revocation of the authorization for the use of antibiotic was the side effects of the active substance fusafungine. It is noted that the fusafungine can cause anaphylactic shock, threatening in rare cases death. Medicine used for the treatment of upper respiratory tract.
“Taking into account non-severe and uncomplicated nature of the course of diseases of upper Airways such as nasopharyngitis, PRAC (the Committee for risk assessment in the field of pharmacovigilance of the European medicines Agency. — NGS.OMSK) gave the opinion that the benefit from the use of fusafungine outweighing the risks”, — said the laboratory “Servier”.
In pharmacies “Farmakopeyka”, “Pharmacy warehouse” and “Family” clients report that the drug is not available in the “Family” warned that “Bioparox” revoked license and on sale will be no more.
